title: Comparing Clinical Outcomes for Radium-223: Do Older Patients Do Worse?
abstract: To examine the clinical benefits and toxicities of223Ra in 2 different age groups of patients with castrate-resistant prostate cancer.
  
  
  
  This was a retrospective study of patients treated with223Ra in 2 tertiary centers. Patients were divided into 2 different groups based on their age (≥72 years old and <72 years old). Treatment toxicities were graded according to Common Terminology Criteria for Adverse Events version 4.0. Comparison of characteristics and outcome was carried out with the Mann-Whitney test and analysis of overall survival with the log-rank test.
  
  
  
  In all, 129 patients were treated during the study period. Clinical benefit was similar in both groups. However, a statistically significant higher proportion of patients in the younger group had previously been treated with docetaxel. There was a higher rate of grade 3 anemia in younger patients.
  
  
  
  In line with other studies,223Ra was well tolerated with minimum toxicities. The significantly higher rate of grade 3 anemia in younger patients may be due to more cautious patient selection in the elderly population.
authors.affiliation: The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom.
authors.forename: Yee Pei
authors.initials: YP
authors.lastname: Song
authors.affiliation: Lancashire Teaching Hospitals NHS Foundation Trust, Preston, United Kingdom.
authors.forename: Tracey
authors.initials: T
authors.lastname: Ellis
authors.affiliation: The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom.
authors.forename: Richard
authors.initials: R
authors.lastname: Walshaw
authors.affiliation: The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom.
authors.forename: Peter
authors.initials: P
authors.lastname: Mbanu
authors.affiliation: Lancashire Teaching Hospitals NHS Foundation Trust, Preston, United Kingdom.
authors.forename: Omi
authors.initials: O
authors.lastname: Parikh
authors.affiliation: The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom.
authors.forename: John
authors.initials: J
authors.lastname: Logue
authors.affiliation: The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom; The University of Manchester, Manchester, United Kingdom. Electronic address: Ananya.Choudhury@christie.nhs.uk.
authors.forename: Ananya
authors.initials: A
authors.lastname: Choudhury
mesh_terms: D000367:Age Factors; D000368:Aged; D000740:Anemia / Q000209:etiology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004739:England; D006801:Humans; D008297:Male; D009503:Neutropenia / Q000209:etiology; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D011883:Radium / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011883:Radium